Sunitinib malate (BioDeep_00000743402)
代谢物信息卡片
Sunitinib malate
化学式: C26H33FN4O7 (532.2333160000001)
中文名称: 苹果酸舒尼替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O
InChI: /t
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents
D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D006133 - Growth Substances > D006131 - Growth Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Zhansheng Jiang, Jiahe Wang, Chenghuan Dao, Mingyu Zhu, Yuan Li, Fangchao Liu, Yangyang Zhao, Jiayue Li, Yinli Yang, Zhanyu Pan. Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.
Apoptosis : an international journal on programmed cell death.
2024 Jun; 29(5-6):681-692. doi:
10.1007/s10495-023-01932-3. [PMID: 38281281] - Huan Liu, Longsheng Wang, Xiaokai Shi, Lei Yin, Wei Zhai, Shenglin Gao, Yonghui Chen, Tao Zhang. Calcium saccharate/DUSP6 suppresses renal cell carcinoma glycolytic metabolism and boosts sunitinib efficacy via the ERK-AKT pathway.
Biochemical pharmacology.
2024 Jun; 224(?):116247. doi:
10.1016/j.bcp.2024.116247. [PMID: 38697311] - Jing Zhao, Dongming Yan, Yue Li, Xiaoqing Xu, Fengling Li, Shuang Zhang, Jingyi Jin, Furong Qiu. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2024 Apr; 1237(?):124100. doi:
10.1016/j.jchromb.2024.124100. [PMID: 38547701] - Xianhua She, Donghong Yin, Qian Guo, Yang Tang, Shuyun Wang, Xuyan Wang. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis.
Scientific reports.
2024 03; 14(1):5592. doi:
10.1038/s41598-024-56335-4. [PMID: 38454105] - Lin Zhang, Liping Liu, Leina Zhao, Xinmei Yuan, Yun Wang, Jing Yang. Clinical Efficacy of Bushen Yiqi Fuzheng Decoction Combined with Sunitinib in the Treatment of Postoperative Patients with Renal Cell Carcinoma and Its Influence on Their Immune Function.
Archivos espanoles de urologia.
2023 Sep; 76(7):538-547. doi:
10.56434/j.arch.esp.urol.20237607.67. [PMID: 37867340] - Yan Sun, Liang Zhu, Pian Liu, Huan Zhang, Feng Guo, Xin Jin. ZDHHC2-mediated AGK palmitoylation activates AKT/mTOR signaling to reduce sunitinib sensitivity in renal cell carcinoma.
Cancer research.
2023 Apr; ?(?):. doi:
10.1158/0008-5472.can-22-3105. [PMID: 37078777] - Leonardo Gomes Souza, Ailton Antonio Sousa-Junior, Bertilha Alves Santana Cintra, Jorge Luiz Vieira Dos Anjos, Thaís Leite Nascimento, Lívia Palmerston Mendes, Marcelo de Souza Vieira, Rafael do Nascimento Ducas, Marize Campos Valadares, Sebastião Antônio Mendanha, Eliana Martins Lima. Pre-clinical safety of topically administered sunitinib-loaded lipid and polymeric nanocarriers targeting corneal neovascularization.
International journal of pharmaceutics.
2023 Mar; 635(?):122682. doi:
10.1016/j.ijpharm.2023.122682. [PMID: 36754184] - Juan Jin, Yuhao Xie, Jin-Shi Zhang, Jing-Quan Wang, Shi-Jie Dai, Wen-Fang He, Shou-Ye Li, Charles R Ashby, Zhe-Sheng Chen, Qiang He. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
2023 Mar; 67(?):100929. doi:
10.1016/j.drup.2023.100929. [PMID: 36739809] - Yihui Pan, Xuanxuan Lu, Guannan Shu, Junjie Cen, Jun Lu, Mi Zhou, Kangbo Huang, Jiaqi Dong, Jiaying Li, Haishan Lin, Hongde Song, Quanhui Xu, Hui Han, Zhenhua Chen, Wei Chen, Junhang Luo, Jinhuan Wei, Jiaxing Zhang. Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma.
Cancer research.
2023 01; 83(1):103-116. doi:
10.1158/0008-5472.can-21-3432. [PMID: 36264173] - Xiaofang Liu, Weixuan Hong, Lie Wang, Zaizhong Zhang. Sunitinib-associated posterior reversible encephalopathy syndrome in a patient with a gastrointestinal stromal tumor.
Asian journal of surgery.
2022 10; 45(10):1964-1965. doi:
10.1016/j.asjsur.2022.04.034. [PMID: 35525690] - Victor Gaillard, Albane Lhuillier, Cécile Bigot, Laure Pierard, Philippe Trensz, Mickael Burgy, Caroline Schuster, Gabriel Malouf, Aurélie Fritsch, Hervé Lang, Thibault Tricard, Delphine Borchiellini, Lionnel Geoffrois, Philippe Barthelemy. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2022 Aug; 30(8):6583-6591. doi:
10.1007/s00520-022-07088-1. [PMID: 35484315] - Ruizhe Liu, Kaifeng Qiu, Junyan Wu, Yanqing Jiang, Peihao Wu, Jianxin Pang. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
Immunotherapy.
2022 Aug; 14(11):859-869. doi:
10.2217/imt-2021-0156. [PMID: 35754404] - Umberto Capitanio, Giuseppe Fallara, Daniele Raggi, Luigi Nocera, Alessandro Larcher, Federico Belladelli, Isaline Rowe, Alberto Briganti, Andrea Salonia, Pierre Karakiewicz, Francesco Montorsi, Alberto Martini, Andrea Necchi. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence.
Current problems in cancer.
2022 Aug; 46(4):100875. doi:
10.1016/j.currproblcancer.2022.100875. [PMID: 35679628] - Sarah J Welsh, Nicola Thompson, Anne Warren, Andrew N Priest, Tristan Barrett, Stephan Ursprung, Ferdia A Gallagher, Fulvio Zaccagna, Grant D Stewart, Kate M Fife, Athena Matakidou, Andrea J Machin, Wendi Qian, Victoria Ingleson, Jean Mullin, Antony C P Riddick, James N Armitage, Stephen Connolly, Timothy G Q Eisen. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
BJU international.
2022 08; 130(2):244-253. doi:
10.1111/bju.15600. [PMID: 34549873] - Ya-Li Wang, Hui Liu, Li-Lin Wan, Ke-Hao Pan, Jia-Xuan Ni, Qiang Hu, Xu Bin, Ming Chen. Characterization and function of biomarkers in sunitinib-resistant renal carcinoma cells.
Gene.
2022 Jul; 832(?):146514. doi:
10.1016/j.gene.2022.146514. [PMID: 35550407] - Irbaz Bin Riaz, Qurat Ul Ain Riaz Sipra, Syed Arsalan Ahmed Naqvi, Huan He, Rabbia Siddiqi, Mahnoor Islam, Noureen Asghar, Waleed Ikram, Wenxin Xu, Hongfong Liu, Parminder Singh, Thai Huu Ho, Mehmet Asim Bilen, Yousef Zakharia, Alan Haruo Bryce, Mohammad Hassan Murad. Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis.
Critical reviews in oncology/hematology.
2022 Jul; 175(?):103706. doi:
10.1016/j.critrevonc.2022.103706. [PMID: 35537621] - Clément Carbasse, Fanny Leenhardt, William Jacot, Caroline Perrier, Frederic Pinguet, Marie Viala. Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort.
British journal of clinical pharmacology.
2022 07; 88(7):3370-3377. doi:
10.1111/bcp.15285. [PMID: 35178745] - Yann-Alexandre Vano, Réza Elaidi, Letuan Phan, Wolf Herman Fridman, Catherine Sautès-Fridman, Stéphane Oudard. Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.
The Lancet. Oncology.
2022 07; 23(7):e318. doi:
10.1016/s1470-2045(22)00331-x. [PMID: 35772460] - Yasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, Maureen J B Aarts, Michael Jewett, Igle Jan de Jong, Jean-Baptiste Lattouf, Harm H E van Melick, Lori Wood, Peter Mulders, Sylvie Rottey, John Wagstaff, Patricia Zondervan, Tom Powles, Anouk Neven, Laurence Collette, Bertrand Tombal, John Haanen, Axel Bex. Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
BJU international.
2022 07; 130(1):68-75. doi:
10.1111/bju.15625. [PMID: 34706141] - Florence Joly, Jean-Marie Michot, Louis Marie Dourthe, Aude Fléchon, Hakim Mahammedi, Denis Maillet, Guillaume Mouillet, Damien Pouessel, Frédéric Rolland, Delphine Topart, Laurence Albiges. [Metastatic renal cell carcinoma: Management of toxicities of combinations].
Bulletin du cancer.
2022 Jul; 109(7-8):844-861. doi:
10.1016/j.bulcan.2022.04.019. [PMID: 35738914] - Laurence Albiges, Daniel Y C Heng, Jae Lyun Lee, Stephen Walker, Anders Mellemgaard, Lone Ottesen, Melanie M Frigault, Anne L'Hernault, Jonathan Wessen, Toni Choueiri, Mathilde Cancel, Sabina Signoretti. Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data.
European journal of cancer (Oxford, England : 1990).
2022 07; 170(?):158-168. doi:
10.1016/j.ejca.2022.04.021. [PMID: 35640484] - Robert J Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, Maria T Bourlon, Amishi Y Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher M Hocking, Elizabeth R Kessler, Howard Gurney, Yoshihiko Tomita, Jens Bedke, Joshua Zhang, Burcin Simsek, Christian Scheffold, Andrea B Apolo, Toni K Choueiri. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.
The Lancet. Oncology.
2022 07; 23(7):888-898. doi:
10.1016/s1470-2045(22)00290-x. [PMID: 35688173] - Daniel M Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez, Maria T Bourlon, Stephen Huo, Viviana Del Tejo, Ella X Du, Xiaoran Yang, Keith A Betts, Toni K Choueiri, Bradley McGregor. Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma.
Clinical drug investigation.
2022 Jul; 42(7):611-622. doi:
10.1007/s40261-022-01170-6. [PMID: 35696045] - Claire Antoun, Loic Choffel, Alexandre Frontczak, Marine Gross-Goupil, Antoine Thiery-Vuillemin. Adjuvant therapy in renal cell carcinoma: Ready, steady, should we go?.
Bulletin du cancer.
2022 Jul; 109(7-8):750-755. doi:
10.1016/j.bulcan.2022.04.015. [PMID: 35717225] - Andrew J Smith, Prashant Ruchaya, Robert Walmsley, Kathleen E Wright, Fiona C Lewis-McDougall, Jacquelyn Bond, Georgina M Ellison-Hughes. Receptor tyrosine kinase inhibitors negatively impact on pro-reparative characteristics of human cardiac progenitor cells.
Scientific reports.
2022 Jun; 12(1):10132. doi:
10.1038/s41598-022-13203-3. [PMID: 35710779] - Bibian M E Tullemans, Sanne L N Brouns, Frauke Swieringa, Siamack Sabrkhany, Franchette W P J van den Berkmortel, Natascha A J B Peters, Peter de Bruijn, Stijn L W Koolen, Johan W M Heemskerk, Maureen J B Aarts, Marijke J E Kuijpers. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study.
BMC cancer.
2022 Jun; 22(1):653. doi:
10.1186/s12885-022-09676-0. [PMID: 35698081] - Yan Jiao, Ye Gao, JiaYao Wang, Huanxiao An, Yi Xiang Li, Xi Zhang. Intelligent porphyrin nano-delivery system for photostimulated and targeted inhibition of angiogenesis.
International journal of pharmaceutics.
2022 Jun; 621(?):121805. doi:
10.1016/j.ijpharm.2022.121805. [PMID: 35526698] - Brian I Rini, Javid J Moslehi, Marc Bonaca, Manuela Schmidinger, Laurence Albiges, Toni K Choueiri, Robert J Motzer, Michael B Atkins, John Haanen, Mariangela Mariani, Jing Wang, Subramanian Hariharan, James Larkin. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2022 Jun; 40(17):1929-1938. doi:
10.1200/jco.21.01806. [PMID: 35239416] - Michal Rihacek, Iveta Selingerova, Ivo Kocak, Ilona Kocakova, Eva Rihackova, Dalibor Valik, Jaroslav Sterba. Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)-Exploring Its Possible Clinical Relevance in Cancer Patients.
Current oncology (Toronto, Ont.).
2022 Jun; 29(6):4138-4147. doi:
10.3390/curroncol29060330. [PMID: 35735439] - Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C Goh, Masatoshi Eto, Lee Bennett, Jinyi Wang, Jie Janice Pan, Todd L Saretsky, Rodolfo F Perini, Cixin Steven He, Kalgi Mody, David Cella. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
The Lancet. Oncology.
2022 06; 23(6):768-780. doi:
10.1016/s1470-2045(22)00212-1. [PMID: 35489363] - Robert J Motzer, David F McDermott, Bernard Escudier, Mauricio Burotto, Toni K Choueiri, Hans J Hammers, Philippe Barthélémy, Elizabeth R Plimack, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Howard Gurney, Christian K Kollmannsberger, Marc-Oliver Grimm, Carlos Barrios, Yoshihiko Tomita, Daniel Castellano, Viktor Grünwald, Brian I Rini, M Brent McHenry, Chung-Wei Lee, Jennifer McCarthy, Flavia Ejzykowicz, Nizar M Tannir. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
Cancer.
2022 06; 128(11):2085-2097. doi:
10.1002/cncr.34180. [PMID: 35383908] - Jose A Karam, Maneka Puligandla, Keith T Flaherty, Robert G Uzzo, Surena F Matin, Michael R Pins, Christopher G Wood, Christopher Kane, Michael A S Jewett, Se Eun Kim, Janice P Dutcher, Robert S DiPaola, Naomi B Haas. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
BJU international.
2022 06; 129(6):718-722. doi:
10.1111/bju.15587. [PMID: 34480522] - Jacob Wise, Raj Tiwari, Sophie O'Halloran, Lauren Fleshner, Susan Nguyen, Karen Hersey, Nazanin Fallah-Rad, Neil Fleshner. Time trends for drug specific adverse events in patients on sunitinib; implications for remote monitoring.
The Canadian journal of urology.
2022 Jun; 29(3):11136-11141. doi:
NULL. [PMID: 35691034] - Khushboo A Gandhi, Amit Joshi, Parsshava Mehta, Murari Gurjar, Pallavi Rane, Jyoti Sharma, Anand Patil, Manjunath Nookala, Vanita Noronha, Kumar Prabhash, Vikram Gota. Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer.
Cancer chemotherapy and pharmacology.
2022 Jun; 89(6):751-759. doi:
10.1007/s00280-022-04432-4. [PMID: 35441269] - Aaron R Lim, Benjamin G Vincent, Alissa M Weaver, W Kimryn Rathmell. Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma.
Cancer gene therapy.
2022 Jun; 29(6):683-696. doi:
10.1038/s41417-021-00345-1. [PMID: 34088993] - Chengwu Xiao, Wei Zhang, Meimian Hua, Huan Chen, Bin Yang, Ye Wang, Qing Yang. RNF7 inhibits apoptosis and sunitinib sensitivity and promotes glycolysis in renal cell carcinoma via the SOCS1/JAK/STAT3 feedback loop.
Cellular & molecular biology letters.
2022 May; 27(1):36. doi:
10.1186/s11658-022-00337-5. [PMID: 35562668] - Yuanlei Chen, Zeyi Lu, Chao Qi, Chenhao Yu, Yang Li, Wang Huan, Ruyue Wang, Wenqin Luo, Danyang Shen, Lifeng Ding, Liangliang Ren, Haiyun Xie, Dingwei Xue, Mingchao Wang, Kangxin Ni, Liqun Xia, Jun Qian, Gonghui Li. N6-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma.
Molecular cancer.
2022 05; 21(1):111. doi:
10.1186/s12943-022-01549-1. [PMID: 35538475] - Kazuhiro Yamamoto, Satoshi Nishiyama, Makoto Kunisada, Masashi Iida, Takahiro Ito, Takeshi Ioroi, Hiroo Makimoto, Tomohiro Omura, Kenichi Harada, Masato Fujisawa, Chikako Nishigori, Ikuko Yano. Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study).
The oncologist.
2022 05; 27(5):e384-e392. doi:
10.1093/oncolo/oyab067. [PMID: 35285503] - Antoine El Kaddissi, Guillemette Guilhem Ducleon, Félix Lefort, Garvey Mezepo, Alexandre Frontczak, Morgan Goujon, Guillaume Mouillet, Hamadi Almotlak, Marine Gross-Goupil, Antoine Thiery-Vuillemin. Metastatic renal cell cancer and first-line combinations: for which patients? (focus on tolerance and health-related quality of life).
Bulletin du cancer.
2022 May; 109(2S):2S19-2S30. doi:
10.1016/s0007-4551(22)00235-1. [PMID: 35760467] - Géraldine Pignot. Surgical management in metastatic renal cell carcinoma.
Bulletin du cancer.
2022 May; 109(2S):2S59-2S65. doi:
10.1016/s0007-4551(22)00239-9. [PMID: 35760472] - Lajos Markó, Anne Dörr, Peter Linz, Anton H van den Meiracker, Ingrid M Garrelds, Titus Kuehne, Ralf Dechend, A H Jan Danser, Anne Flörcken, Dominik N Müller. Effect of Sunitinib Treatment on Skin Sodium Accumulation in Patients With Renal Cancer: a Pilot Study.
Hypertension (Dallas, Tex. : 1979).
2022 05; 79(5):e103-e105. doi:
10.1161/hypertensionaha.122.19079. [PMID: 35189705] - Ronan Flippot, Violaine Gorgeu, Marc Pujalte, Emeline Colomba, Carolina Alves, Luigi Cerbone, Lucia Carril, Lisa Derosa, Bernard Escudier, Laurence Albigès. Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma.
Bulletin du cancer.
2022 May; 109(2S):2S31-2S38. doi:
10.1016/s0007-4551(22)00236-3. [PMID: 35760468] - Hsu-Cheng Ko, Huai-Pao Lee, Jiann-Der Wu, Tsung-Liang Ma, Cheng-Huang Shen, Chang-Te Lin, Ming-Chin Cheng, Yeong-Chin Jou. Sunitinib-related high-grade proteinuria and allograft dysfunction in a kidney recipient: a rare case report.
BMC nephrology.
2022 04; 23(1):150. doi:
10.1186/s12882-022-02789-5. [PMID: 35436872] - Myra E van Linde, Mariette Labots, Cyrillo G Brahm, Koos E Hovinga, Philip C De Witt Hamer, Richard J Honeywell, Richard de Goeij-de Haas, Alex A Henneman, Jaco C Knol, Godefridus J Peters, Henk Dekker, Sander R Piersma, Thang V Pham, William P Vandertop, Connie R Jiménez, Henk M W Verheul. Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 04; 28(8):1595-1602. doi:
10.1158/1078-0432.ccr-21-1933. [PMID: 35165100] - Xin Ge, Mengdie Li, Jianxing Yin, Zhumei Shi, Yao Fu, Ningwei Zhao, Hongshan Chen, Longxiyu Meng, Xinjian Li, Zhibin Hu, Xiaozhi Zhao, Hongqian Guo, Xu Qian. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma.
Molecular cell.
2022 04; 82(7):1249-1260.e7. doi:
10.1016/j.molcel.2022.01.029. [PMID: 35216667] - Wen Li, GaiXia Li, LuQuan Cao. Circular RNA Eps15-homology domain-containing protein 2 induce resistance of renal cell carcinoma to sunitinib via microRNA-4731-5p/ABCF2 axis.
Bioengineered.
2022 04; 13(4):9729-9740. doi:
10.1080/21655979.2022.2059960. [PMID: 35412955] - Florent Ferrer, Jonathan Chauvin, Jean-Laurent Deville, Joseph Ciccolini. Adaptive dosing of sunitinib in a metastatic renal cell carcinoma patient: when in silico modeling helps to go quicker to the point.
Cancer chemotherapy and pharmacology.
2022 04; 89(4):565-569. doi:
10.1007/s00280-021-04383-2. [PMID: 35147741] - Brian I Rini, Michael B Atkins, Elizabeth R Plimack, Denis Soulières, Raymond S McDermott, Jens Bedke, Sophie Tartas, Boris Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, Przemyslaw Langiewicz, Lori A Wood, Hans Hammers, Cynthia G Silber, Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
European urology oncology.
2022 04; 5(2):225-234. doi:
10.1016/j.euo.2021.05.007. [PMID: 34244116] - Y Tomita, R J Motzer, T K Choueiri, B I Rini, H Miyake, H Uemura, L Albiges, Y Fujii, Y Umeyama, J Wang, M Mariani, M Schmidinger. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
ESMO open.
2022 04; 7(2):100450. doi:
10.1016/j.esmoop.2022.100450. [PMID: 35397432] - E Grande, T Alonso-Gordoa, O Reig, E Esteban, D Castellano, X Garcia-Del-Muro, M J Mendez, J García-Donas, M González Rodríguez, J A Arranz-Arija, P Lopez-Criado, J Molina-Cerrillo, B Mellado, C Alvarez-Fernandez, G De Velasco, M A Cuéllar-Rivas, R M Rodríguez-Alonso, J F Rodríguez-Moreno, C Suarez-Rodriguez. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
ESMO open.
2022 04; 7(2):100463. doi:
10.1016/j.esmoop.2022.100463. [PMID: 35405437] - Lena Stange, Kristin Elizabeth Lucia, Adnan Ghori, Peter Vajkoczy, Marcus Czabanka, Thomas Broggini. LPPR5 Expression in Glioma Affects Growth, Vascular Architecture, and Sunitinib Resistance.
International journal of molecular sciences.
2022 Mar; 23(6):. doi:
10.3390/ijms23063108. [PMID: 35328529] - Sang Eun Park, Wonju Kim, Ji-Ye Hong, Dayeon Kang, Seulki Park, Jungyo Suh, Dalsan You, Yun-Yong Park, Nayoung Suh, Jung Jin Hwang, Choung-Soo Kim. miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.
Scientific reports.
2022 03; 12(1):3537. doi:
10.1038/s41598-022-07468-x. [PMID: 35241735] - Yasemin Gündoğdu, Orhan Cem Deniz, Didem Saka, Gürhan Şişman, Sibel Erdamar, İftihar Köksal. Sunitinib induced colitis manifesting as invasive diarrhea in a patient with renal cell carcinoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
2022 Mar; 28(2):516-518. doi:
10.1177/10781552211061183. [PMID: 34791942] - Daniel M Geynisman, Ella X Du, Xiaoran Yang, Selvam R Sendhil, Viviana Del Tejo, Keith A Betts, Stephen Huo. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
Future oncology (London, England).
2022 Mar; 18(10):1219-1234. doi:
10.2217/fon-2021-1109. [PMID: 34939424] - Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Angela Dalia Ricci, Matteo Rosellini, Andrea Marchetti, Rodolfo Montironi, Andrea Ardizzoni, Francesco Massari. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
European urology focus.
2022 Mar; 8(2):514-521. doi:
10.1016/j.euf.2021.03.001. [PMID: 33714725] - Laurence Albiges, Nizar M Tannir, Mauricio Burotto, David McDermott, Elizabeth R Plimack, Philippe Barthélémy, Camillo Porta, Thomas Powles, Frede Donskov, Saby George, Christian K Kollmannsberger, Howard Gurney, Marc-Oliver Grimm, Yoshihiko Tomita, Daniel Castellano, Brian I Rini, Toni K Choueiri, David Leung, Shruti Shally Saggi, Chung-Wei Lee, M Brent McHenry, Robert J Motzer. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
European urology.
2022 03; 81(3):266-271. doi:
10.1016/j.eururo.2021.10.001. [PMID: 34750035] - G Vivanet, L Gervaso, A Laffi, M Rubino, F Spada, N Fazio. Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile.
Expert opinion on drug safety.
2022 Mar; 21(3):303-310. doi:
10.1080/14740338.2022.2000964. [PMID: 34724869] - Robert J Motzer, Toni K Choueiri, David F McDermott, Thomas Powles, Yann-Alexandre Vano, Saurabh Gupta, Jin Yao, Celine Han, Ron Ammar, Simon Papillon-Cavanagh, Shruti S Saggi, M Brent McHenry, Petra Ross-Macdonald, Megan Wind-Rotolo. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
Journal for immunotherapy of cancer.
2022 03; 10(3):. doi:
10.1136/jitc-2021-004316. [PMID: 35304405] - Ritesh R Suthar, Nilendu Purandare, Sneha Shah, Archi Agrawal, Ameya Puranik, Venkatesh Rangarajan. Sunitinib-Induced Myositis Detected on 18F-FDG PET/CT.
Clinical nuclear medicine.
2022 Mar; 47(3):e311-e312. doi:
10.1097/rlu.0000000000004035. [PMID: 35025809] - Anthony Markham. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.
Targeted oncology.
2022 03; 17(2):193-201. doi:
10.1007/s11523-022-00866-1. [PMID: 35175500] - Mehmet A Bilen, Brian I Rini, Martin H Voss, James Larkin, John B A G Haanen, Laurence Albiges, Lance C Pagliaro, Eric G Voog, Elaine T Lam, Nikolay Kislov, Bradley A McGregor, Aly-Khan A Lalani, Bo Huang, Alessandra di Pietro, Stan Krulewicz, Paul B Robbins, Toni K Choueiri. Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2022 02; 28(4):738-747. doi:
10.1158/1078-0432.ccr-21-1688. [PMID: 34789480] - Alan Chan, Carolyn Dang, Jessica Wisniewski, Xiuhua Weng, Edward Hynson, Lixian Zhong, Leslie Wilson. A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma.
American journal of clinical oncology.
2022 02; 45(2):66-73. doi:
10.1097/coc.0000000000000884. [PMID: 34991104] - Arman Alimohammadi, Harun Fajkovic, Mesut Remzi, Shahrokh Shariat, Manuela Schmidinger. Recent pharmacological approaches for the treatment of renal cell carcinoma.
Expert review of clinical pharmacology.
2022 Feb; 15(2):187-195. doi:
10.1080/17512433.2022.2053521. [PMID: 35285369] - Álvaro Pinto, Oscar Reig, Clara Iglesias, Enrique Gallardo, Xavier García-Del Muro, Teresa Alonso, Georgia Anguera, Cristina Suárez, José Muñoz-Langa, Laura Villalobos-León, Ángel Rodríguez-Sánchez, Nuria Lainez, Esther Martínez-Ortega, Marc Campayo, Alejandro Velastegui, Alejo Rodriguez-Vida, José C Villa-Guzmán, Maria J Méndez-Vidal, Gustavo Rubio, Iciar García, Laia Capdevila, Julio Lambea, Sergio Vázquez, Ovidio Fernández, Susana Hernando-Polo, Sara Cerezo, Carmen Santander, Rosa García-Marrero, Francisco Zambrana, Aranzazu González-Del Alba, Martin Lazaro-Quintela, Daniel Castellano, Isabel Chirivella, Urbano Anido, Antonio Viana, Arancha García, Miguel Sotelo, María Garrido Arévalo, Jesús García-Donas, Carolina Hernández, M Victoria Bolós, Julia Llinares, Miguel A Climent. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Clinical genitourinary cancer.
2022 02; 20(1):25-34. doi:
10.1016/j.clgc.2021.09.006. [PMID: 34789409] - NULL. Title Not Available.
Aktuelle Urologie.
2022 02; 53(1):16-18. doi:
10.1055/a-1559-4893. [PMID: 35078256] - David Cella, Robert J Motzer, Cristina Suarez, Steven I Blum, Flavia Ejzykowicz, Melissa Hamilton, Joel F Wallace, Burcin Simsek, Joshua Zhang, Cristina Ivanescu, Andrea B Apolo, Toni K Choueiri. Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.
The Lancet. Oncology.
2022 02; 23(2):292-303. doi:
10.1016/s1470-2045(21)00693-8. [PMID: 35032437] - Stefanie D Krens, Sasja F Mulder, Nielka P van Erp. Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites.
Cancer chemotherapy and pharmacology.
2022 02; 89(2):271-274. doi:
10.1007/s00280-021-04377-0. [PMID: 34853912] - Weiyin Gao, Shouhua Zhang, Li Guorong, Queling Liu, Anyi Zhu, Fu Gui, Yan Zou, Yiguo Wu, Yang Luo, Zhengdong Hong. Nc886 promotes renal cancer cell drug-resistance by enhancing EMT through Rock2 phosphorylation-mediated β-catenin nuclear translocation.
Cell cycle (Georgetown, Tex.).
2022 02; 21(4):340-351. doi:
10.1080/15384101.2021.2020431. [PMID: 34974812] - Brian A Costello, Nrupen A Bhavsar, Yousef Zakharia, Sumanta K Pal, Ulka Vaishampayan, Heather Jim, Mayer N Fishman, Ana M Molina, Christos E Kyriakopoulos, Che-Kai Tsao, Leonard J Appleman, Benjamin A Gartrell, Arif Hussain, Walter M Stadler, Neeraj Agarwal, Russell K Pachynski, Thomas E Hutson, Hans J Hammers, Christopher W Ryan, Jack Mardekian, Azah Borham, Daniel J George, Michael R Harrison. A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.
Clinical genitourinary cancer.
2022 02; 20(1):1-10. doi:
10.1016/j.clgc.2021.07.002. [PMID: 34364796] - Robert J Motzer, Thomas Powles, Michael B Atkins, Bernard Escudier, David F McDermott, Boris Y Alekseev, Jae-Lyun Lee, Cristina Suarez, Daniil Stroyakovskiy, Ugo De Giorgi, Frede Donskov, Begoña Mellado, Romain Banchereau, Habib Hamidi, Omara Khan, Veronica Craine, Mahrukh Huseni, Nick Flinn, Sarita Dubey, Brian I Rini. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
JAMA oncology.
2022 Feb; 8(2):275-280. doi:
10.1001/jamaoncol.2021.5981. [PMID: 34940781] - Wentao Liu, Dianyun Ren, Wei Xiong, Xin Jin, Liang Zhu. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Journal of experimental & clinical cancer research : CR.
2022 Jan; 41(1):38. doi:
10.1186/s13046-022-02253-0. [PMID: 35081978] - Satoshi Tamada, Chihiro Kondoh, Nobuaki Matsubara, Ryuichi Mizuno, Go Kimura, Satoshi Anai, Yoshihiko Tomita, Masafumi Oyama, Naoya Masumori, Takahiro Kojima, Hiroaki Matsumoto, Mei Chen, Mengran Li, Kenji Matsuda, Yoshinobu Tanaka, Brian I Rini, Hirotsugu Uemura. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study.
International journal of clinical oncology.
2022 Jan; 27(1):154-164. doi:
10.1007/s10147-021-02014-7. [PMID: 34800178] - Kojiro Ohba, Yasuyoshi Miyata, Kensuke Mitsunari, Tsuyoshi Matsuda, Yuta Mukae, Yuichiro Nakamura, Tomohiro Matsuo, Hideki Sakai. Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up.
Urologia internationalis.
2022; 106(6):623-629. doi:
10.1159/000520652. [PMID: 35045411] - Zhen-Qian Qin, Kong-Dong Li, He-Zhen Chu, Xue-Feng Yuan, Hai-Feng Shi, Jie Gu, Yi-Min Xie. Blocking stanniocalcin 2 reduces sunitinib resistance in clear cell renal cell carcinoma.
Neoplasma.
2022 Jan; 69(1):145-154. doi:
10.4149/neo_2021_210823n1206. [PMID: 34881630] - Fabio Catalano, Sara Elena Rebuzzi, Veronica Murianni, Alessandra Damassi, Valentino Martelli, Roberto Borea, Gian Andrea Rollandi, Giuseppe Fornarini. Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient.
Anti-cancer drugs.
2022 01; 33(1):e724-e729. doi:
10.1097/cad.0000000000001152. [PMID: 34261919] - Ali Mahdi, Tong Jiao, Yahor Tratsiakovich, Bernhard Wernly, Jiangning Yang, Claes-Göran Östenson, A H Jan Danser, John Pernow, Zhichao Zhou. Therapeutic Potential of Sunitinib in Ameliorating Endothelial Dysfunction in Type 2 Diabetic Rats.
Pharmacology.
2022; 107(3-4):160-166. doi:
10.1159/000520728. [PMID: 34929688] - Aimin Jiang, Jialin Meng, Wenliang Gong, Zhonghua Zhang, Xinxin Gan, Jie Wang, Zhenjie Wu, Bing Liu, Le Qu, Linhui Wang. Elevated SNRPA1, as a Promising Predictor Reflecting Severe Clinical Outcome via Effecting Tumor Immunity for ccRCC, Is Related to Cell Invasion, Metastasis, and Sunitinib Sensitivity.
Frontiers in immunology.
2022; 13(?):842069. doi:
10.3389/fimmu.2022.842069. [PMID: 35281041] - Hossam Kamli, Evan P Owens, David A Vesey, Rajagopalan Prasanna, Li Li, Glenda C Gobe, Christudas Morais. Overcoming sunitinib resistance with tocilizumab in renal cell carcinoma: Discordance between in vitro and in vivo effects.
Biochemical and biophysical research communications.
2022 01; 586(?):42-48. doi:
10.1016/j.bbrc.2021.11.069. [PMID: 34826699] - Damien Ambrosetti, Michael Coutts, Charlotte Paoli, Matthieu Durand, Delphine Borchiellini, Christopher Montemagno, Olivia Rastoin, Arnaud Borderie, Renaud Grepin, Nathalie Rioux-Leclercq, Jean-Christophe Bernhard, Gilles Pagès, Maeva Dufies. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy.
BJU international.
2022 01; 129(1):80-92. doi:
10.1111/bju.15506. [PMID: 34107167] - Peng Zhou, Zheng Liu, Henglong Hu, Yuchao Lu, Jun Xiao, Yanan Wang, Yang Xun, Qidong Xia, Chenqian Liu, Jia Hu, Shaogang Wang. Comprehensive Analysis of Senescence Characteristics Defines a Novel Prognostic Signature to Guide Personalized Treatment for Clear Cell Renal Cell Carcinoma.
Frontiers in immunology.
2022; 13(?):901671. doi:
10.3389/fimmu.2022.901671. [PMID: 35720278] - Takahiro Ito, Kazuhiro Yamamoto, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Ikuko Yano. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule.
Journal of clinical pharmacy and therapeutics.
2022 Jan; 47(1):81-88. doi:
10.1111/jcpt.13517. [PMID: 34669974] - Kang-Bo Huang, Yi-Hui Pan, Guan-Nan Shu, Hao-Hua Yao, Xi Liu, Mi Zhou, Jin-Huan Wei, Zhen-Hua Chen, Jun Lu, Zi-Hao Feng, Wei Chen, Hui Han, Zhou-San Zheng, Jun-Hang Luo, Jia-Xing Zhang. Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis.
Cancer letters.
2021 12; 523(?):121-134. doi:
10.1016/j.canlet.2021.10.003. [PMID: 34626691] - Cheng Tang, GenYi Qu, Yong Xu, Guang Yang, Jiawei Wang, Maolin Xiang. An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma.
Aging.
2021 12; 13(24):26046-26062. doi:
10.18632/aging.203797. [PMID: 34954690] - Stephane Oudard, Nadine Benhamouda, Bernard Escudier, Patrice Ravel, Thi Tran, Emeline Levionnois, Sylvie Negrier, Philippe Barthelemy, Jean François Berdah, Marine Gross-Goupil, Cora N Sternberg, Petri Bono, Camillo Porta, Ugo De Giorgi, Omi Parikh, Robert Hawkins, Martin Highley, Jochen Wilke, Thomas Decker, Corinne Tanchot, Alain Gey, Magali Terme, Eric Tartour. Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.
Cells.
2021 12; 11(1):. doi:
10.3390/cells11010017. [PMID: 35011579] - Meredith M Regan, Opeyemi A Jegede, Charlene M Mantia, Thomas Powles, Lillian Werner, Robert J Motzer, Nizar M Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H Voss, Elizabeth R Plimack, Toni K Choueiri, Brian I Rini, Hans J Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B Atkins, David F McDermott. Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2021 12; 27(24):6687-6695. doi:
10.1158/1078-0432.ccr-21-2283. [PMID: 34759043] - Hajime Sasagawa, Kazuyuki Numakura, Gaku Nakamura, Takashi Kukimoto, Akane Kikuchi, Ryuichiro Sagehashi, Ryohei Yamamoto, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Mitsuru Saito, Shintaro Narita, Takamitsu Inoue, Shigeru Satoh, Tomonori Habuchi. [Successful Re-Administration of Nivolumab in Patient with Metastatic Renal Cell Carcinoma : A Case Report].
Hinyokika kiyo. Acta urologica Japonica.
2021 Dec; 67(12):525-528. doi:
10.14989/actauroljap_67_12_525. [PMID: 34991292] - Heidrun Rexer, Peter Hammerer. Title Not Available.
Aktuelle Urologie.
2021 Dec; 52(6):519-520. doi:
10.1055/a-1469-0502. [PMID: 34847602] - Mathias Brugel, Thomas Walter, Bernard Goichot, Denis Smith, Côme Lepage, Christine Do Cao, Vincent Hautefeuille, Vinciane Rebours, Guillaume Cadiot, Louis de Mestier. Efficacy of treatments for VIPoma: A GTE multicentric series.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
2021 Dec; 21(8):1531-1539. doi:
10.1016/j.pan.2021.08.001. [PMID: 34404601] - Mariangela Massaccesi, Luca Boldrini, Angela Romano, Ernesto Rossi, Giovanni Schinzari, Elisabetta Lepre, Maria Antonietta Gambacorta, Vincenzo Valentini. Unconventional radiotherapy to enhance immunotherapy efficacy in bulky tumors: a case report.
Immunotherapy.
2021 12; 13(18):1457-1463. doi:
10.2217/imt-2020-0289. [PMID: 34664999] - Gang Wei, Honglin Sun, Kai Dong, Libing Hu, Qi Wang, Qian Zhuang, Yan Zhu, Xianjing Zhang, Yaodi Shao, Huiru Tang, Zhenfei Li, Suzhen Chen, Junxi Lu, Yibing Wang, Xinxin Gan, Tao P Zhong, Dingkun Gui, Xiaoyong Hu, Linhui Wang, Junli Liu. The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy.
Cell metabolism.
2021 10; 33(10):2021-2039.e8. doi:
10.1016/j.cmet.2021.08.012. [PMID: 34508696] - Takashi Kobayashi, Ario Takeuchi, Hiroyuki Nishiyama, Masatoshi Eto. Current status and future perspectives of immunotherapy against urothelial and kidney cancer.
Japanese journal of clinical oncology.
2021 Oct; 51(10):1481-1492. doi:
10.1093/jjco/hyab121. [PMID: 34389866] - Alessandro Rizzo, Veronica Mollica, Matteo Santoni, Francesco Massari. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis.
Expert review of gastroenterology & hepatology.
2021 Oct; 15(10):1225-1232. doi:
10.1080/17474124.2021.1948328. [PMID: 34167420] - Yun Peng, Shiqiang Dong, Yuxuan Song, Dingkun Hou, Lili Wang, Bowen Li, Haitao Wang. Key sunitinib-related biomarkers for renal cell carcinoma.
Cancer medicine.
2021 10; 10(19):6917-6930. doi:
10.1002/cam4.4206. [PMID: 34402193] - Maria Carmen Mir, Laurence Albiges, Axel Bex, Milan Hora, Gianluca Giannarini, Alessandro Volpe, Morgan Rouprêt. Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges?.
European urology oncology.
2021 10; 4(5):843-850. doi:
10.1016/j.euo.2020.05.010. [PMID: 32553707] - Arnaud Méjean, Alain Ravaud, Simon Thezenas, Christine Chevreau, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwenaelle Gravis, Frederic Rolland, Claude Linassier, Eric Lechevallier, Stephane Oudard, Brigitte Laguerre, Marine Gross-Goupil, Jean Christophe Bernhard, Sandra Colas, Laurence Albiges, Thierry Lebret, Jean-Marc Treluyer, Marc-Olivier Timsit, Bernard Escudier. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?.
European urology.
2021 10; 80(4):417-424. doi:
10.1016/j.eururo.2021.06.009. [PMID: 34187771] - Eduardo Corona-Rodarte, Antonio Olivas-Martínez, Yuly A Remolina-Bonilla, Judith G Domínguez-Cherit, Elaine T Lam, Maria T Bourlon. Do we need skin toxicity? Association of immune checkpoint inhibitor and tyrosine kinase inhibitor-related cutaneous adverse events with outcomes in metastatic renal cell carcinoma.
International journal of dermatology.
2021 Oct; 60(10):1242-1247. doi:
10.1111/ijd.15583. [PMID: 33871070] - Zhao Xu, Cong Zhang, Xu Yu, Heng Zheng, Li Xu. Microwave-assisted solid-phase synthesis of nitrogen-doping carbon dot with good solvent compatibility and its sensing of sunitinib.
Analytical and bioanalytical chemistry.
2021 Oct; 413(25):6435-6447. doi:
10.1007/s00216-021-03609-9. [PMID: 34401928] - Yohei Sekino, Kenshiro Takemoto, Daiki Murata, Takashi Babasaki, Kohei Kobatake, Hiroyuki Kitano, Kenichiro Ikeda, Keisuke Goto, Shogo Inoue, Tetsutaro Hayashi, Daiki Taniyama, Masanobu Shigeta, Kazuya Kuraoka, Koji Mita, Mayumi Kaneko, Kazuhiro Sentani, Naohide Oue, Jun Teishima. CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Anticancer research.
2021 Oct; 41(10):4875-4883. doi:
10.21873/anticanres.15301. [PMID: 34593435] - Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H Giles, Milan Hora, Thomas B Lam, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
European urology.
2021 10; 80(4):393-397. doi:
10.1016/j.eururo.2021.04.042. [PMID: 34074559]